Showing 1 - 7 of 7 Immune System Diseases

Status: Open Not Enrolling

Investigator: Terry Clyburn

Study Coordinator: Adrienne New

Phone: 713.441.3250

This study is designed to observe the long term clinical outcomes of patient-specific knee arthroplasty in patients with osteoarthritis. ... Read more >

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Michelle Prystash

Phone: 713.441.6564

Open label, multi-center dose escalation and dose expansion study designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with wild-typ ... Read more >

Status: Open Not Enrolling

Investigator: Lisa Kopas

Study Coordinator: Elmira Ramos

Phone: 713.441.3248

The purpose of this research is to study a medical device that is designed to produce lung volume reduction. This device is called the PulmonX Endobronchial Valve (EBV). It has not been approved by the Food and Drug Administration (FDA) and is c ... Read more >

Status: Open Not Enrolling

Investigator: Lisa Kopas

Study Coordinator: Vivian Vasquez Escamilla

Phone: 713.363.7005

This registry is a post market observational, prospective, multi-center registry. It is designed to evaluate patient experience with the RePneu™ device for the relief of the emphysema symptoms and the continued collection of safety and effective ... Read more >

Status: Enrolling

Investigator: Ahmed Gaber

Study Coordinator: Darrel Cleere

Phone: 713.441.6232

Rabbit antithymocyte globulin (rATG) is approved for the treatment of acute rejection following kidney transplantation and is routinely administered as a series of 5-7 consecutive daily doses via central intravenous catheter. This prolonged cour ... Read more >

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Michelle Prystash

Phone: 713.441.6564

RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and ... Read more >

Live Chat Available